Wide Awake Open Carpal Tunnel Release With or Without a Tourniquet

NCT ID: NCT06172400

Last Updated: 2023-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-09

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare open carpal tunnel release using local anesthesia with or without a tourniquet. The main questions it aims to answer are:

1. Do the tourniquet cause more procedural pain?
2. Does the use of tourniquet affect the outcome after the procedure? Participants will be randomized to either local anesthesia with a tourniquet or local anesthesia with adrenaline, and undrgo standard open carpal tunnel release.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carpal Tunnel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Touniquet

Local injection of Mepivacaine (10 mg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start. Use of a forearm tourniquet at the pressure of 250 mmHg.

Group Type ACTIVE_COMPARATOR

Mepivacaine, Combinations

Intervention Type DRUG

Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.

Adrenaline

Local injection of Mepivacaine (10 mg/ml) and adrenaline (5 mcg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start. Forearm tourniquet applied but not inflated.

Group Type EXPERIMENTAL

Mepivacaine, Combinations

Intervention Type DRUG

Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mepivacaine, Combinations

Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary idiopathic CTS
* Age 18 or older
* Symptoms of classic or probable carpal tunnel syndrome according to Katz hand diagram
* No previous wide awake hand surgical procedures under local anesthesia
* No planned concomitant procedures

Exclusion Criteria

* Recurrent carpal tunnel syndrome
* Vibration induced neuropathy
* Polyneuropathy
* Cognitive impairment
* Anxiety disorder
* Swedish language insufficiency
* Active substance abuse
* Allergy to local anesthesia or adrenaline
* Patient refusal to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Skane

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jesper Nordenskjöld, MD, PhD

Role: CONTACT

Phone: 0739706570

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-04670

Identifier Type: -

Identifier Source: org_study_id